Carregant...
Phase 2 trial of Sorafenib in Children and Young Adults with Refractory Solid Tumors: A Report from the Children’s Oncology Group
BACKGROUND: Sorafenib is an oral small molecule inhibitor of multiple kinases controlling tumor growth and angiogenesis. The purpose of this phase 2 study was to determine the response rate of sorafenib and gain further information on the associated toxicities, pharmacokinetics, and pharmacodynamics...
Guardat en:
| Publicat a: | Pediatr Blood Cancer |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4515771/ https://ncbi.nlm.nih.gov/pubmed/26207356 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25548 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|